Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

First reported human isolation of Staphylococcus delphini.

Magleby R, Bemis DA, Kim D, Carroll KC, Castanheira M, Kania SA, Jenkins SG, Westblade LF.

Diagn Microbiol Infect Dis. 2019 Jan 26. pii: S0732-8893(18)30400-0. doi: 10.1016/j.diagmicrobio.2019.01.014. [Epub ahead of print]

PMID:
30955895
2.

Updated Prevalence of mcr-Like Genes among Escherichia coli and Klebsiella pneumoniae in the SENTRY Program and Characterization of mcr-1.11 Variant.

Deshpande LM, Hubler C, Davis AP, Castanheira M.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02450-18. doi: 10.1128/AAC.02450-18. Print 2019 Apr. No abstract available.

PMID:
30917984
3.

Characterization of β-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 trial (REPRISE) for ceftazidime-avibactam: Correlation of efficacy against β-lactamase producers.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Antimicrob Agents Chemother. 2019 Mar 25. pii: AAC.02655-18. doi: 10.1128/AAC.02655-18. [Epub ahead of print]

PMID:
30910899
4.

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S79-S94. doi: 10.1093/ofid/ofy358. eCollection 2019 Mar.

5.

Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States.

Mendes RE, Jones RN, Woosley LN, Cattoir V, Castanheira M.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S69-S78. doi: 10.1093/ofid/ofz004. eCollection 2019 Mar.

6.

Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016).

Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46. doi: 10.1093/ofid/ofy293. eCollection 2019 Mar.

7.

Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program.

Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S23-S33. doi: 10.1093/ofid/ofy347. eCollection 2019 Mar.

9.
10.

In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.

Castanheira M, Davis AP, Serio AW, Krause KM, Mendes RE.

Diagn Microbiol Infect Dis. 2019 May;94(1):73-77. doi: 10.1016/j.diagmicrobio.2018.10.023. Epub 2018 Dec 5.

PMID:
30661726
11.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.

Diagn Microbiol Infect Dis. 2019 May;94(1):93-102. doi: 10.1016/j.diagmicrobio.2018.11.021. Epub 2018 Nov 30.

PMID:
30642717
12.

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient.

Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, Brizendine KD, Mathers AJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01551-18. doi: 10.1128/AAC.01551-18. Print 2019 Jan.

PMID:
30578403
13.

Does a ghrelin stimulus during zebrafish embryonic stage modulate its performance on the long-term?

Navarro-Guillén C, Dias J, Rocha F, Castanheira MF, Martins CIM, Laizé V, Gavaia PJ, Engrola S.

Comp Biochem Physiol A Mol Integr Physiol. 2019 Feb;228:1-8. doi: 10.1016/j.cbpa.2018.10.019. Epub 2018 Oct 25.

PMID:
30393112
14.

Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates.

Costello SE, Deshpande LM, Davis AP, Mendes RE, Castanheira M.

J Glob Antimicrob Resist. 2019 Mar;16:278-285. doi: 10.1016/j.jgar.2018.10.020. Epub 2018 Oct 30.

PMID:
30389638
15.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam.

Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, Jain R.

Infect Drug Resist. 2018 Sep 17;11:1499-1510. doi: 10.2147/IDR.S173804. eCollection 2018.

16.

Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype.

Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA, MacVane SH.

mSphere. 2018 Sep 26;3(5). pii: e00408-18. doi: 10.1128/mSphere.00408-18.

17.

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01587-18. doi: 10.1128/AAC.01587-18. Print 2018 Dec.

PMID:
30224535
18.
19.

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01230-18. doi: 10.1128/AAC.01230-18. Print 2018 Oct.

20.

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Sader HS, Castanheira M, Mendes RE, Flamm RK.

J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.

PMID:
30060117
21.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M.

J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.

PMID:
29901750
23.

Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.

Deshpande LM, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Sep 1;73(9):2314-2322. doi: 10.1093/jac/dky188.

PMID:
29878213
24.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.

Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00313-18. doi: 10.1128/AAC.00313-18. Print 2018 Aug.

25.
26.

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.

Pfaller MA, Rhomberg PR, Castanheira M.

Diagn Microbiol Infect Dis. 2018 Sep;92(1):43-45. doi: 10.1016/j.diagmicrobio.2018.04.005. Epub 2018 Apr 13.

PMID:
29735424
27.

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.

Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2018 Jul 1;73(7):1880-1887. doi: 10.1093/jac/dky099.

PMID:
29659858
28.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.

PMID:
29654893
29.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
30.

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.

Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.

PMID:
29510189
31.
32.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.

Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.

33.

CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests.

Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, Koeth L, Sei K; CLSI Methods Development and Standardization Working Group of the Subcommittee on Antimicrobial Susceptibility Testing.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01934-17. doi: 10.1128/JCM.01934-17. Print 2018 Apr. Review.

34.

Predicting cardiometabolic disturbances from waist-to-height ratio: findings from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) baseline.

Castanheira M, Chor D, Braga JU, Cardoso LO, Griep RH, Molina MDCB, da Fonseca MJM.

Public Health Nutr. 2018 Apr;21(6):1028-1035. doi: 10.1017/S136898001700338X. Epub 2018 Jan 9.

PMID:
29310740
35.

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Pfaller MA, Sader HS, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Apr 1;73(4):916-922. doi: 10.1093/jac/dkx485.

PMID:
29294031
36.

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.

PMID:
29277526
37.

Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.

Munson E, Huband MD, Castanheira M, Fedler KA, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):324-328. doi: 10.1016/j.diagmicrobio.2017.11.019. Epub 2017 Dec 5.

PMID:
29276104
38.

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02125-17. doi: 10.1128/AAC.02125-17. Print 2018 Mar.

39.

Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients.

Reidenberg BE, Wanner C, Polsky B, Castanheira M, Shelip A, Stalleicken D, Pfaffle AE.

Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):661-663. doi: 10.1007/s10096-017-3157-7. Epub 2017 Dec 6.

40.

The application of in vitro surveillance data for antibacterial dose selection.

Flamm RK, Sader HS, Castanheira M, Jones RN.

Curr Opin Pharmacol. 2017 Oct;36:130-138. doi: 10.1016/j.coph.2017.10.009. Epub 2017 Nov 11. Review.

PMID:
29136540
41.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

43.

Cognitive appraisal of environmental stimuli induces emotion-like states in fish.

Cerqueira M, Millot S, Castanheira MF, Félix AS, Silva T, Oliveira GA, Oliveira CC, Martins CIM, Oliveira RF.

Sci Rep. 2017 Oct 13;7(1):13181. doi: 10.1038/s41598-017-13173-x.

44.
45.

Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California.

Le J, Turner N, Deshpande LM, Davis AP, Castanheira M.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):303-304. doi: 10.1016/j.diagmicrobio.2017.07.005. Epub 2017 Jul 14.

PMID:
28987268
46.

Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride.

Castanheira M, Duncan LR, Rhomberg PR, Sader HS.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):305-309. doi: 10.1016/j.diagmicrobio.2017.08.011. Epub 2017 Aug 24.

PMID:
28969934
47.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.

Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.

48.

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01045-17. doi: 10.1128/AAC.01045-17. Print 2017 Nov.

49.

Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00906-17. doi: 10.1128/AAC.00906-17. Print 2017 Oct.

50.

Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.

J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.

PMID:
28735053

Supplemental Content

Loading ...
Support Center